市场调查报告书
商品编码
1471194
多模态成像市场:按产品、技术、应用和最终用户划分 - 2024-2030 年全球预测Multimodal Imaging Market by Product (Multimodal Imaging Equipment, Reagents, Software), Technology (PET/CT, PET/MRI, SPECT/CT), Application, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年多模态成像市场规模为28.3亿美元,预计2024年将达30亿美元,2030年将达43亿美元,复合年增长率为6.18%。
多模态成像包括先进成像技术的开发、製造、分销和利用,这些技术将两种或多种显像模式整合到单一设备或系统中。对慢性病早期诊断的日益关注、技术的进步以及患有与老龄化相关疾病的全球人口老化正在增加多模态成像的使用。然而,多模态影像系统的高昂采集费用和维护成本可能会阻碍其普及,特别是在医疗保健预算有限的新兴国家。也就是说,人工智慧驱动的演算法预计将有助于简化多种模式的资料分析,同时提高诊断准确性,同时减少处理时间。
主要市场统计 | |
---|---|
基准年[2023] | 28.3亿美元 |
预测年份 [2024] | 30亿美元 |
预测年份 [2030] | 43亿美元 |
复合年增长率(%) | 6.18% |
产品:疾病诊断多模态影像设备的需求增加
多模态影像设备采用多种模态,例如电脑断层扫描 (CT)、光学同调断层扫描(OCT)、磁振造影(MRI) 和超音波正子扫描(PET),来检测各种生物组织并拍摄结构的详细影像。试剂透过增强体内不同组织之间的对比或突出与疾病相关的特定分子标靶,在多模态成像中发挥重要作用。多模态成像中使用的常见试剂包括用于 PET/SPECT 研究的放射性同位素、用于 MRI 研究的钆显影剂、用于 CT 研究的碘化合物以及用于光学成像的萤光染料。多模态成像软体解决方案能够撷取、处理、分析和视觉化来自各种显像模式的资料。在处理需要整合各种模态影像的复杂疾病时,多模态成像软体至关重要。
应用:扩大多模态影像在癌症领域的应用
在循环系统领域,多模态影像为医疗专业人员提供有关心臟组织的结构、功能和灌注的详细资讯。典型的诊断影像技术包括超音波心动图、核心臟病学和心臟磁振造影(MRI)。临床应用包括利用多模态影像来增强诊断、治疗计划和疾病监测的各种医疗领域。 CT(电脑断层扫描)、MRI、PET(正子断层扫描)和超音波等技术应用于各种临床环境,包括整形外科、胃肠病学、妇科和小儿科。在神经学应用中,多模态成像对于透过结合结构资料和功能资讯来了解大脑功能和诊断阿兹海默症和多发性硬化症等神经系统疾病至关重要。肿瘤学多模态影像对于早期癌症检测、监测治疗反应和识别治疗后復发具有重要意义。
这是技术。 PET/CT技术因其高灵敏度和特异性而成为重要的应用领域。
PET/CT(正子断层扫描/电脑断层扫描)是一种将 PET 的功能资讯与 CT 的解剖细节结合的影像技术。它用于肿瘤学、心臟病学和神经病学的诊断、分期和治疗效果评估。此外,PET/磁振造影(PET/MRI) 是一种混合技术,它将 PET 获得的代谢资讯与 MRI 提供的高解析度软组织对比度相结合。这种模式可用于儿童肿瘤学、神经退化性疾病的脑部影像和心血管影像。 SPECT/CT(单光子发射电脑断层扫描)是一种高度通用的混合成像方法,结合了功能性 SPECT资料和解剖 CT 资讯。它主要用于整形外科、心臟和肿瘤诊断成像。
最终用户:诊断中心对多模态成像的需求不断增长
多模态成像技术被学术和研究机构使用,因为它们需要先进的工具来更好地了解各种生物过程。多模态成像使研究人员能够利用高解析度影像研究复杂的细胞结构、分子相互作用和疾病病理学。诊断中心提供重要的诊断服务,如放射学、超音波、磁振造影(MRI)、电脑断层扫描(CT)、核子医学(NM)、光学同调断层扫描(OCT)和正子断层扫描(PET)扫描。慢性病的增加和人口老化增加了医院环境对先进影像处理系统的需求。
区域洞察
在美国和加拿大,人口老化和慢性病的迅速增加正在增加对先进诊断工具的需求。对研发的投资已产生大量专利申请,展示了该领域的创新。随着学术、临床和产业相关人员促进创新,欧盟 (EU) 国家的多模态成像市场也不断成长。在中东和非洲地区,医疗基础设施的改善正在为多模态成像市场创造巨大的成长机会。各国政府正在投资医疗保健,以应对癌症和心血管疾病等非传染性疾病的增加,其中先进影像技术发挥关键作用。由于快速都市化、医疗设施扩张和可支配收入增加等因素,中国、日本、印度和其他亚太国家的多模态成像市场正在稳步扩张。
FPNV定位矩阵
FPNV定位矩阵对于评估多模态影像市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对多模态成像市场中供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该细分市场竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:包括新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:包括对未来技术、研发活动以及突破性产品开发的见解。
1.多模态成像市场的市场规模和预测是多少?
2.在多模态影像市场的预测期内,我们应该考虑投资哪些产品和应用?
3.多模态成像市场的技术趋势和法规结构是什么?
4.多模态成像市场主要厂商的市场占有率为何?
5. 进入多模态影像市场的合适模式和策略手段是什么?
[187 Pages Report] The Multimodal Imaging Market size was estimated at USD 2.83 billion in 2023 and expected to reach USD 3.00 billion in 2024, at a CAGR 6.18% to reach USD 4.30 billion by 2030.
Multimodal imaging encompasses developing, producing, distributing, and utilizing advanced imaging technologies that combine two or more imaging modalities within a single device or system.The rising focus on early diagnosis of chronic diseases, technological advancements, an aging global population with age-related ailments increases the use of multimodal imaging. However, multimodal imaging systems' high acquisition and maintenance costs may hinder widespread adoption, especially in emerging economies with limited healthcare budgets. Nevertheless, AI-powered algorithms are expected to help streamline data analysis from multiple modalities simultaneously improving diagnostic accuracy while reducing processing time.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.83 billion |
Estimated Year [2024] | USD 3.00 billion |
Forecast Year [2030] | USD 4.30 billion |
CAGR (%) | 6.18% |
Product: Increasing demand for multimodal imaging equipments for disease diagnostics
Multimodal imaging equipment employs multiple modalities such as computed tomography (CT), optical coherence tomography (OCT), magnetic resonance imaging (MRI), ultrasound positron emission tomography (PET) to capture detailed images of various biological tissues and structures. Reagents play a crucial role in multimodal imaging by enhancing the contrast between different tissues in the body or highlighting specific molecular targets related to diseases. Some common reagents used in multimodal imaging are radioisotopes for PET/Single photon emission computed tomography (SPECT) scans, gadolinium-based contrast agents for MRI, iodinated compounds for CT scans, and fluorescent dyes for optical imaging. Software solutions in multimodal imaging enable the acquisition, processing, analysis, and visualization of data from different imaging modalities. Multimodal imaging software is essential when dealing with complex diseases requiring the integration of images from various modalities.
Application: Expanding use of multimodal imaging for oncology
In cardiology applications, multimodal imaging provides healthcare professionals with detailed information regarding cardiac tissue structure, function, and perfusion. Some prominent imaging techniques include echocardiography, nuclear cardiology, and cardiac magnetic resonance imaging (MRI). Clinical applications encompass various medical disciplines that utilize multimodal imaging to enhance diagnosis, treatment planning, and disease monitoring. Techniques such as computed tomography (CT), MRI, positron emission tomography (PET), and ultrasound are employed in diverse clinical settings, including orthopedics, gastroenterology, gynecology, and pediatrics. In neurology applications, multimodal imaging is vital in understanding brain function and diagnosing neurological disorders such as Alzheimer's or multiple sclerosis by combining structural data with functional information. Oncologic multimodal imaging has significance in early detection of cancer, monitoring treatment response, and identifying recurrence post-therapy
Technology: Significant applications of PET/CT technology owing to its high sensitivity and specificity
Positron Emission Tomography/Computed Tomography (PET/CT) is an imaging technique that combines the functional information from PET with the anatomical details of CT. It is utilized in oncology, cardiology, and neurology applications for diagnosis, staging, and assessment of treatment response. Moreover, PET/Magnetic Resonance Imaging (PET/MRI) is a hybrid technology combining the metabolic information obtained from PET with the high-resolution soft tissue contrast provided by MRI. This modality benefits pediatric oncology, brain imaging for neurodegenerative diseases, and cardiovascular imaging. Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) is a versatile hybrid imaging modality that combines functional SPECT data with anatomical CT information. It is primarily employed in orthopedic, cardiac, and oncological imaging.
End-User: Proliferating demand for multimodal imaging in diagnostic centers
Academic and research institutes use multimodal imaging technology as they need advanced tools to offer better insights into various biological processes. It enables researchers to study intricate cellular structures, molecular interactions, and disease pathology with high-resolution images. Diagnostic centers provide crucial diagnostic services, including radiology, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), nuclear medicine (NM), optical coherence tomography (OCT), and positron emission tomography (PET) scans. The increased chronic illness and the growing geriatric population have raised the need for advanced imaging systems in hospital settings.
Regional Insights
In the United States and Canada, there has been a rising demand for advanced diagnostic tools due to an aging population and surge in prevalence of chronic diseases. Investments in research and development have led to numerous patents being filed, showcasing innovation in this sector. European Union countries have also seen growth in the multimodal imaging market with increasing collaboration between academia, clinical institutions, and industry players driving innovation. In the Middle East and Africa region, improving healthcare infrastructure has created a significant growth opportunities multimodal imaging market. Governments are investing in healthcare to address the rising incidences of non-communicable diseases such as cancer and cardiovascular disorders where advanced imaging plays a crucial role. China, Japan, India, and other Asia Pacific countries are experiencing robust expansion of their multimodal imaging markets due to factors such as rapid urbanization, expanding healthcare facilities, and increasing disposable income.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Multimodal Imaging Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multimodal Imaging Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Multimodal Imaging Market, highlighting leading vendors and their innovative profiles. These include Bruker Corporation, Canon Inc., GE Healthcare, Infraredx Inc., International Business Machines Corporation, Koninklijke Philips N.V., Mediso Ltd., MR Solutions Ltd., Neusoft Medical Systems Co., Ltd., Northridge Tri-Modality Imaging, Inc., PerkinElmer, Inc., Shanghai United Imaging Healthcare Co., Ltd., Siemens AG, Spectrum Dynamics Medical, Inc., and Topcon Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Multimodal Imaging Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multimodal Imaging Market?
3. What are the technology trends and regulatory frameworks in the Multimodal Imaging Market?
4. What is the market share of the leading vendors in the Multimodal Imaging Market?
5. Which modes and strategic moves are suitable for entering the Multimodal Imaging Market?